Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids

Chemistry and Physics of Lipids

Volumn 165, Issue 4, 2012, Pages 462-474

  Gatt, Shimon ^a   Dagan, Arie ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Cancer; Ceramide; Fluorescent sphingolipids; Sphingolipid analogs; Sphingolipidoses; Sphingolipids

Indexed keywords

ANTINEOPLASTIC AGENT; CERAMIDE; CHAPERONE; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE;

APOPTOSIS; CANCER CELL DESTRUCTION; CELL SURVIVAL; CONFERENCE PAPER; DISEASE ASSOCIATION; ENZYME SUBSTRATE; HUMAN; HYDROLYSIS; LIPIDOSIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CERAMIDES; DRUG DISCOVERY; HUMANS; NEOPLASMS; SPHINGOLIPIDOSES; SPHINGOLIPIDS;

MUS;

EID: 84860714751     PISSN: 00093084     EISSN: 18732941     Source Type: Journal    
DOI: 10.1016/j.chemphyslip.2012.02.006     Document Type: Conference Paper

References (58)

1. N. Andrieu-Abadie, V. Gouaze, R. Salvayre, and T. Levade Ceramide in apoptosis signaling: relationship with oxidative stress Free Radic. Biol. Med. 31 2001 717 728
2. T.H. Beckham, S. Elojeimy, J.C. Cheng, L.S. Turner, S.R. Hoffman, J.S. Norris, and X. Liu Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials Expert Opin. Ther. Targets 14 2010 529 539
3. M. Bektas, P.S. Jolly, C. Muller, J. Eberle, S. Spiegel, and C.C. Geilen Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression Oncogene 24 2005 178 187
4. E.G. Bligh, and W.J. Dyer A rapid method of total lipid extraction and purification Can. J. Biochem. Physiol. 37 1959 911 917
5. R.O. Brady The lipid storage diseases: new concepts and control Ann. Intern. Med. 82 1975 257 261
6. C.E. Chalfant, and S. Spiegel Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling J. Cell Sci. 118 2005 4605 4612
7. A. Dagan, V. Agmon, S. Gatt, and T. Dinur Synthesis of fluorescent substrates and their application to study of sphingolipid metabolism in vitro and in intact cells Methods Enzymol. 312 2000 293 304
8. A. Dagan, C. Wang, E. Fibach, and S. Gatt Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death Biochim. Biophys. Acta 1633 2003 161 169
9. P.I. Darroch, A. Dagan, T. Granot, X. He, S. Gatt, and E.H. Schuchman A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death J. Lipid Res. 46 2005 2315 2324
10. R.J. Desnick, and E.H. Schuchman Enzyme replacement and enhancement therapies: lessons from lysosomal disorders Nat. Rev. Genet. 3 2002 954 966
11. T. Dinur, E.H. Schuchman, E. Fibach, A. Dagan, M. Suchi, R.J. Desnick, and S. Gatt Toward gene therapy for Niemann-Pick disease (NPD): separation of retrovirally corrected and noncorrected NPD fibroblasts using a novel fluorescent sphingomyelin Hum. Gene Ther. 3 1992 633 639
12. S. Elojeimy, X. Liu, J.C. McKillop, A.M. El-Zawahry, D.H. Holman, J.Y. Cheng, W.D. Meacham, A.E. Mahdy, A.F. Saad, L.S. Turner, J.T. Cheng, A.D. Dong, J.Y. Bielawska, A. Hannun, and Y.A.J.S. Norris Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy Mol. Ther. 15 2007 1259 1263
13. A.H. Futerman, and Y.A. Hannun The complex life of simple sphingolipids EMBO Rep. 5 2004 777 782
14. S. Gatt Enzymic hydrolysis and synthesis of ceramides J. Biol. Chem. 238 1963 3131 3133
15. T. Granot, D. Milhas, S. Carpentier, A. Dagan, B. Segui, S. Gatt, and T. Levade Caspase-dependent and -independent cell death of Jurkat human leukemia cells induced by novel synthetic ceramide analogs Leukemia 20 2006 392 399
16. A. Haimovitz-Friedman, R.N. Kolesnick, and Z. Fuks Ceramide signaling in apoptosis Br. Med. Bull. 53 1997 539 553
17. K. Hanada, K. Kumagai, N. Tomishige, and T. Yamaji CERT-mediated trafficking of ceramide Biochim. Biophys. Acta 1791 2009 684 691
18. Y.A. Hannun Functions of ceramide in coordinating cellular responses to stress Science 274 1996 1855 1859
19. Y.A. Hannun, and C. Luberto Ceramide in the eukaryotic stress response Trends Cell Biol. 10 2000 73 80
20. Y.A. Hannun, and L.M. Obeid The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind J. Biol. Chem. 277 2002 25847 25850
21. Y.A. Hannun, L.M. Obeid, and R.A. Wolff The novel second messenger ceramide: identification, mechanism of action, and cellular activity Adv. Lipid Res. 25 1993 43 64
22. X. He, N. Okino, R. Dhami, A. Dagan, S. Gatt, H. Schulze, K. Sandhoff, and E.H. Schuchman Purification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinase J. Biol. Chem. 278 2003 32978 32986
23. M. Itoh, T. Kitano, M. Watanabe, T. Kondo, T. Yabu, Y. Taguchi, K. Iwai, M. Tashima, T. Uchiyama, and T. Okazaki Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia Clin. Cancer Res. 9 2003 415 423
24. E.M. Jung, R.D. Griner, R. Mann-Blakeney, and W.B. Bollag A potential role for ceramide in the regulation of mouse epidermal keratinocyte proliferation and differentiation J. Invest. Dermatol. 110 1998 318 323
25. K. Kitatani, J. Idkowiak-Baldys, and Y.A. Hannun The sphingolipid salvage pathway in ceramide metabolism and signaling Cell. Signal. 20 2008 1010 1018
26. R.N. Kolesnick, and M. Kronke Regulation of ceramide production and apoptosis Annu. Rev. Physiol. 60 1998 643 665
27. R.H. Lachmann, and F.M. Platt Substrate reduction therapy for glycosphingolipid storage disorders Expert Opin. Investig. Drugs 10 2001 455 466
28. M.J. Lee, S. Thangada, K.P. Claffey, N. Ancellin, C.H. Liu, M. Kluk, M. Volpi, R.I. Sha'afi, and T. Hla Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate Cell 99 1999 301 312
29. Y.J. Lee, and A.A. Amoscato TRAIL and ceramide Vitam. Horm. 67 2004 229 255
30. X. Liu, S. Elojeimy, L.S. Turner, A.E. Mahdy, Y.H. Zeidan, A. Bielawska, J. Bielawski, J.Y. Dong, A.M. El-Zawahry, G.W. Guo, Y.A. Hannun, D.H. Holman, S. Rubinchik, Z. Szulc, T.E. Keane, M. Tavassoli, and J.S. Norris Acid ceramidase inhibition: a novel target for cancer therapy Front. Biosci. 13 2008 2293 2298
31. C. Luberto, and Y.A. Hannun Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C? J. Biol. Chem. 273 1998 14550 14559
32. M. Maceyka, S.G. Payne, S. Milstien, and S. Spiegel Sphingosine kinase, sphingosine-1-phosphate, and apoptosis Biochim. Biophys. Acta 1585 2002 193 201
33. A.E. Mahdy, J.C. Cheng, J. Li, S. Elojeimy, W.D. Meacham, L.S. Turner, A. Bai, C.R. Gault, A.S. McPherson, N. Garcia, T.H. Beckham, A. Saad, A. Bielawska, J. Bielawski, Y.A. Hannun, T.E. Keane, M.I. Taha, H.M. Hammouda, J.S. Norris, and X. Liu Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer Mol. Ther. 17 2009 430 438
34. M. Mimeault, R. Hauke, and S.K. Batra Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies Clin. Pharmacol. Ther. 83 2008 673 691
35. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
36. D.W. Nicholson, A. Ali, N.A. Thornberry, J.P. Vaillancourt, C.K. Ding, M. Gallant, Y. Gareau, P.R. Griffin, M. Labelle, and Y.A. Lazebnik Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis Nature 376 1995 37 43
37. J. Ohanian, and V. Ohanian Sphingolipids in mammalian cell signalling Cell. Mol. Life Sci. 58 2001 2053 2068
38. A. Olivera, and S. Spiegel Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens Nature 365 1993 557 560
39. B. Oskouian, and J.D. Saba Cancer treatment strategies targeting sphingolipid metabolism Adv. Exp. Med. Biol. 688 2010 185 205
40. J.H. Park, and E.H. Schuchman Acid ceramidase and human disease Biochim. Biophys. Acta 1758 2006 2133 2138
41. G.M. Pastores, and S. Sathe A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders Drugs RD 7 2006 339 348
42. G.A. Patwardhan, and Y.Y. Liu Sphingolipids and expression regulation of genes in cancer Prog. Lipid Res. 50 2011 104 114
43. J.D. Qin, L. Weiss, S. Slavin, S. Gatt, and A. Dagan Synthetic, non-natural analogs of ceramide elevate cellular ceramide, inducing apoptotic death to prostate cancer cells and eradicating tumors in mice Cancer Invest. 28 2010 535 543
44. N.S. Radin Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come? Eur. J. Biochem. 268 2001 193 204
45. N.S. Radin Killing tumours by ceramide-induced apoptosis: a critique of available drugs Biochem. J. 371 2003 243 256
46. C.P. Reynolds, B.J. Maurer, and R.N. Kolesnick Ceramide synthesis and metabolism as a target for cancer therapy Cancer Lett. 206 2004 169 180
47. E. Ruckhaberle, A. Rody, K. Engels, R. Gaetje, G. von Minckwitz, S. Schiffmann, S. Grosch, G. Geisslinger, U. Holtrich, T. Karn, and M. Kaufmann Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer Breast Cancer Res. Treat. 112 2008 41 52
48. P.P. Ruvolo Intracellular signal transduction pathways activated by ceramide and its metabolites Pharmacol. Res. 47 2003 383 392
49. P.P. Ruvolo, F. Gao, W.L. Blalock, X. Deng, and W.S. May Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX J. Biol. Chem. 276 2001 11754 11758
50. L.K. Ryland, T.E. Fox, X. Liu, T.P. Loughran, and M. Kester Dysregulation of sphingolipid metabolism in cancer Cancer Biol. Ther. 11 2011 138 149
51. M. Selzner, A. Bielawska, M.A. Morse, H.A. Rudiger, D. Sindram, Y.A. Hannun, and P.A. Clavien Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer Cancer Res. 61 2001 1233 1240
52. D. Shida, K. Takabe, D. Kapitonov, S. Milstien, and S. Spiegel Targeting SphK1 as a new strategy against cancer Curr. Drug Targets 9 2008 662 673
53. L.S. Shihabuddin, S. Numan, M.R. Huff, J.C. Dodge, J. Clarke, S.L. Macauley, W. Yang, T.V. Taksir, G. Parsons, M.A. Passini, F.H. Gage, and G.R. Stewart Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology J. Neurosci. 24 2004 10642 10651
54. S. Spiegel Sphingosine 1-phosphate: a prototype of a new class of second messengers J. Leukoc. Biol. 65 1999 341 344
55. C. Swanton, M. Marani, O. Pardo, P.H. Warne, G. Kelly, E. Sahai, F. Elustondo, J. Chang, J. Temple, A.A. Ahmed, J.D. Brenton, J. Downward, and B. Nicke Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs Cancer Cell 11 2007 498 512
56. R. Whittington, and K.L. Goa Alglucerase. A review of its therapeutic use in Gaucher's disease Drugs 44 1992 72 93
57. G. Yang, L. Badeanlou, J. Bielawski, A.J. Roberts, Y.A. Hannun, and F. Samad Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome Am. J. Physiol. Endocrinol. Metab. 297 2009 E211 E224
58. A. Zimran, and D. Elstein Gaucher disease and the clinical experience with substrate reduction therapy Philos. Trans. R. Soc. Lond. B: Biol. Sci. 358 2003 961 966